<DOC>
	<DOCNO>NCT02345135</DOCNO>
	<brief_summary>Death Ataxia telangiectasia ( A-T ) usually due cancer chronic lung failure around 20 year age . Despite low lymphocyte count ( CD3 , CD4 , CD8 CD19 ) , IgA IgG subclass deficiency opportunistic acute severe respiratory infection rare . The prevailing wisdom immunoglobulin replacement therapy necessary patient . However placebo control trial perform far . The aim trial investigate prevalence mild severe respiratory infection / chronic cough classical A-T patient compare healthy control .</brief_summary>
	<brief_title>Susceptibility Infections Ataxia Telangiectasia</brief_title>
	<detailed_description>Ataxia telangiectasia autosomal recessive multisystem disorder characterize progressive ataxia , conjunctival telangiectasia , humoral cellular immunodeficiency , increased radiosensitivity increase risk cancer ( Boder E , Pediatrics , 1957 ) . Most patient die 2nd 3rd decade life due respiratory failure cause progressive ( interstitial ) lung disease due malignancy ( Schroeder SA , Pediatr Pulmonol , 2010 ) . In 1995 sequence mutate AT gene ( ATM ) chromosome 11q22-23 identify . Main problem besides progressive neurodegeneration recurrent infection upper low respiratory tract growth retardation malnutrition . These problem cause mutation ATM gene chromosome 11 , encode protein several key function control cell cycle apoptosis ( Savitsky K et al. , Hum Mol Gen , 1995 ) . Several work already show patient AT variable immunodeficiency characterize low lymphocyte count , lack Immunoglobulin A ( IgA ) , Immunoglobulin G subclass ( IgG2 4 ) specific pneumococcal antibody ( Schubert R , Clin Exp Immunol , 2002 ) . The course disease dependent AT mutation respectively residual kinase activity ATM find 10 % A-T patient . These patient describe ` variant ATs´ good prognosis regard immunodeficiency , susceptibility infection possible growth retardation malnutrition ( Verhagen M , Hum Mutat , 2012 ) . Despite evidence humoral immunodeficiency treatment polyvalent immunoglobulin ( IgG ) practice generally . In ` Clinical Workshop Ataxia Teleangiectasia´ , take place Frankfurt January 2011 , investigator find percentage A-T patient , supplement immunoglobulin 10 % 60 % depend different clinical centres.The Goethe University Childrens Hospital Frankfurt , big A-T centre Germany , take care 40 A-T patient . At moment 15 % patient treated immunoglobulin . Some observation show progress chronic lung disease prevent usage immunoglobulin . By it´s clear way patient suffer increased susceptibility infection substitution immunoglobulin need . The aim trial investigate incidence , intensity duration infection patient A-T compare age match healthy control .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Ataxia Telangiectasia</mesh_term>
	<criteria>AT : clinically and/or genetically diagnose AT No IgG treatment point include study Healthy control : healthy child adult match gender age age 2 45 year write informed consent age &lt; 2 &gt; 45 year patient treat IgGreplacement regularly Other disease influence immune system ( e.g . diabetes mellitus , malignancy , dialysisdependent renal failure )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>